TNFRSF9, T-cell antigen ILA, ILA, TNF Receptor Superfamily Member 9, T-Cell Antigen 4-1BB Homolog, 4-1BB Ligand Receptor, CD137 Antigen, CDw137, CD137, Interleukin-Activated Receptor, Homolog Of Mouse Ly63, Tumor Necrosis Factor Receptor Superfamily, Member 9, Tumor Necrosis Factor Receptor Superfamily Member 9, Induced By Lymphocyte Activation (ILA), Homolog Of Mouse 4-1BB, Receptor Protein 4-1BB, T Cell Antigen ILA, 4-1BB


Tnfrsf9 (encoding CD137) is a candidate gene for the Idd9.3 type 1 diabetes (T1D) susceptibility locus in the nonobese diabetic (NOD) mouse model. CD137 is a member of the tumor necrosis factor (TNF) receptor family. Its alternative names are tumor necrosis factor receptor superfamily member 9 (TNFRSF9), 4-1BB and induced by lymphocyte activation (ILA).

KO Status

RenLite: In Vitro

Drug Information

Drugs in clinical trials: 43
Latest Research Phase: Phase 3 Clinical

Drug Name





Clinical Trials


PF-2566, PF-5082566, PF-05082566

Phase 3 Clinical

Pfizer Pharmaceuticals Ltd (China)

Solid tumours, Ovarian Neoplasms, Lymphoma, B-Cell, Carcinoma, Renal Cell, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Breast Neoplasms, Lymphoma, Follicular, Colorectal Neoplasms, Oropharyngeal Neoplasms, Lymphoma, Non-Hodgkin, Carcinoma, Squamous Cell, Carcinoma, Non-Small-Cell Lung, Melanoma



Phase 2 Clinical

Biotheus Inc

Solid tumours


GEN-1042, BNT-312

Phase 2 Clinical


Solid tumours, Squamous Cell Carcinoma of Head and Neck, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal, Melanoma, Carcinoma, Non-Small-Cell Lung


BMS-66513, BMS-663513

Phase 2 Clinical

Bristol-Myers Squibb Company

Lymphoma, B-Cell, Head and Neck Neoplasms, Solid tumours, Neoplasms, Multiple Myeloma, Colorectal Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Carcinoma, Non-Small-Cell Lung, Leukemia, Lymphocytic, Chronic, B-Cell


PRS-344/ONC0055, PRS-344, PRS-344/S095012, PRS-344S095012, S-095012

Phase 2 Clinical

Pieris Pharmaceuticals Inc, Laboratoires Servier

Solid tumours

Delolimogene mupadenorepvec


Phase 2 Clinical

Lokon Pharma, Uppsala University

Biliary Tract Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Melanoma



Phase 2 Clinical


Solid tumours, Thoracic Neoplasms, Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung


ND-021, NM21-1480, CS-2006, CS2006

Phase 2 Clinical

Numab Therapeutics Ag

Solid tumours, Neoplasms, Carcinoma, Non-Small-Cell Lung



Phase 2 Clinical

Adagene (Suzhou) Ltd

Solid tumours, Lymphoma, Non-Hodgkin


GEN1046, BNT-311, DuoBody-PD-L1x4-1BB, PD-L1x4-1BB

Phase 2 Clinical

Biontech Se, Genmab

Solid tumours, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms, Carcinoma, Transitional Cell, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung





The consensus coding sequences of human breast and colorectal cancers

Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., Velculescu V.E.,

Science 314:268-274(2006)

A novel leucine-rich repeat protein (LRR-1): potential involvement in 4-1BB-mediated signal transduction

Jang I.-K., Lee Z.-H., Kim H.-H., Hill J.M., Kim J.-D., Kwon B.S.,

Mol. Cells 12:304-312(2001)

Molecular and biological characterization of human 4-1BB and its ligand

Alderson M.R., Smith C.A., Tough T.W., Davis-Smith T., Armitage R.J., Falk B., Roux E., Baker E., Sutherland G.R., Din W.S., Goodwin R.G.,

Eur. J. Immunol. 24:2219-2227(1994)

A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family

Schwarz H., Tuckwell J., Lotz M.,

Gene 134:295-298(1993)

Characterization of human homologue of 4-1BB and its ligand

Zhou Z., Kim S., Hurtado J., Lee Z.H., Kim K.K., Pollok K.E., Kwon B.S.,

Immunol. Lett. 45:67-73(1995)

The DNA sequence and biological annotation of human chromosome 1

Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., Bentley D.R.,

Nature 441:315-321(2006)

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)

The MGC Project Team,

Genome Res. 14:2121-2127(2004)

Signal peptide prediction based on analysis of experimentally verified cleavage sites

Zhang Z., Henzel W.J.,

Protein Sci. 13:2819-2824(2004)

4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB

Arch R.H., Thompson C.B.,

Mol. Cell. Biol. 18:558-565(1998)

CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand

Saoulli K., Lee S.Y., Cannons J.L., Yeh W.C., Santana A., Goldstein M.D., Bangia N., DeBenedette M.A., Mak T.W., Choi Y., Watts T.H.,

J. Exp. Med. 187:1849-1862(1998)